This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Oryzon Genomics SA


ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon team is composed by +50 highly qualified professionals located in Barcelona, Boston, NYC and San Diego. 

We have multiple shoots on goal with two uncorrelated clinical Phase II stage compounds, vafidemstat and iadademstat. Iadademstat, the most potent and selective LSD1 inhibitor of the class, is in clinical development for AML and solid tumors. A PoC in elder AML patients has shown strong clinical activity in a Phase II in elder unfit AML patient. Also encouraging signals in 2L-ED-SCLC patients. Currently launching Phase II trials in RR-AML-Flt3mut+ and solid tumors with registrational path defined

In CNS, we are developing vafidemstat, a safe LSD1 inhibitor that has been dosed in +300 subjects so far. After clinical positive results in reducing aggression in a basket trial with psychiatric patients, we are recruiting now in two Phase IIb programs in Borderline personality disorder (Interim analysis 1Q23. Top line results 4Q23) and in SCZ. Furthermore, we are currently launching a personalized program starting with a Phase II trial in Kabuki syndrome with registrational potential.

Oryzon is listed on the Spanish Market (ORY) with a market cap of around $150m. The company has attracted in the last years investors from US, Israel and Europe in several PIPEs led by different US investment banks. We aim a dual listing in Nasdaq.